Fly News Breaks for March 5, 2019
Mar 5, 2019 | 09:03 EDT
Lake Street analyst Thomas Flaten started CTI BioPharma with a Buy rating and $4 price target. The company's targeted indication for pacritinib in myelofibrosis with severe thrombocytopenia represents an unmet clinical need and potential revenue opportunity of $450M, Flaten tells investors in a research note. Further, CTI's other compounds are not being developed for this niche indication, providing a "substantial pay-off" for the company should the clinical development of pacritinib bear fruit, says the analyst.
News For CTIC From the Last 2 Days
There are no results for your query CTIC